Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA, USP Should Set Generic Biologics Standards, Sen. Hatch Proposes

Executive Summary

Generic biologics should be a priority issue for the next FDA commissioner, Sen. Orrin Hatch (R-Utah) says

You may also be interested in...



BIO Likes EU Model For Follow-On Biologics; Standards Are “Appropriate”

The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said

BIO Likes EU Model For Follow-On Biologics; Standards Are “Appropriate”

The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said

Senate Change Puts Hatch, Gregg, Grassley In Line For Key Rx Committees

The transfer of control in the Senate puts Sen. Orrin Hatch (R-Utah) in position to have greater influence in guiding generic drug reform legislation

Related Content

UsernamePublicRestriction

Register

PS040301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel